AbbVie, FutureGen in License Agreement to Develop Next-Gen IBD Therapy

 AbbVie (NYSE: ABBV) and FutureGen Biopharmaceutical (Beijing) Co., Ltd. today announced a license agreement to develop FG-M701, a next generation TL1A antibody for the treatment of IBD currently in preclinical development.

FG-M701 is a fully human monoclonal antibody targeting TL1A, a clinically validated target in IBD. FG-M701 is uniquely engineered with potential best-in-class functional characteristics compared to first-generation TL1A antibodies with the goal to drive greater efficacy and less frequent dosing as a therapy for IBD.

https://www.prnewswire.com/news-releases/abbvie-and-futuregen-announce-license-agreement-to-develop-next-generation-therapy-for-inflammatory-bowel-disease-302171900.html